Founded in 2017 in Oregon, AICON-BIO began by providing comprehensive immunology solutions, specializing in microbiology, ELISA, rapid tests, and IVD raw materials. The company later expanded into molecular diagnostics with a focus on women’s and animal molecular testing. In 2021, AICON-BIO expanded into regenerative biotechnology and cell and gene therapy, specializing in mesenchymal stem cell (MSC) culture technologies. In 2023, the company introduced NeoPL Human Platelet Lysate, a serum-free growth supplement for advanced cell culture, as well as customized multi-chamber cell culture systems to support biotech research and pharmaceutical development. Today, AICON-BIO combines diagnostic innovation with regenerative biotechnology to deliver reliable, high-quality solutions that advance scientific research and clinical practice.